Atai Life Sciences Nv (ATAI)

$2.3

-0.17

(-6.88%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Atai Life Sciences Nv

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 172.0K → 18.0K (in $), with an average decrease of 64.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 44.24M → -18.29M (in $), with an average decrease of 141.3% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 47.7% return, outperforming this stock by 25.4%

Performance

  • $2.23
    $2.54
    $2.30
    downward going graph

    3.26%

    Downside

    Day's Volatility :12.4%

    Upside

    9.45%

    downward going graph
  • $1.02
    $2.85
    $2.30
    downward going graph

    55.65%

    Downside

    52 Weeks Volatility :64.21%

    Upside

    19.3%

    downward going graph

Returns

PeriodAtai Life Sciences NvSector (Health Care)Index (Russel 2000)
3 Months
23.66%
-1.1%
0.0%
6 Months
75.57%
6.7%
0.0%
1 Year
22.34%
3.2%
-0.7%
3 Years
-88.17%
17.2%
-21.3%

Highlights

Market Capitalization
410.0M
Book Value
$1.6
Earnings Per Share (EPS)
-0.43
Wall Street Target Price
10.68
Profit Margin
0.0%
Operating Margin TTM
-30843.68%
Return On Assets TTM
-24.25%
Return On Equity TTM
-25.29%
Revenue TTM
334.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
262.5%
Gross Profit TTM
233.0K
EBITDA
-126.0M
Diluted Eps TTM
-0.43
Quarterly Earnings Growth YOY
-0.97
EPS Estimate Current Year
-0.77
EPS Estimate Next Year
-0.77
EPS Estimate Current Quarter
-0.16
EPS Estimate Next Quarter
-0.17

Analyst Recommendation

Buy
    86%Buy
    13%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Atai Life Sciences Nv(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
17
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 364.35%

Current $2.30
Target $10.68

Technicals Summary

Sell

Neutral

Buy

Atai Life Sciences Nv is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Atai Life Sciences Nv
Atai Life Sciences Nv
36.9%
75.57%
22.34%
-88.17%
-88.17%
Moderna, Inc.
Moderna, Inc.
1.62%
14.36%
-33.07%
-34.3%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.67%
7.24%
9.09%
88.02%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-7.48%
23.09%
47.7%
252.97%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.99%
6.03%
18.9%
82.63%
117.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Atai Life Sciences Nv
Atai Life Sciences Nv
NA
NA
NA
-0.77
-0.25
-0.24
NA
1.6
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.28
26.28
1.51
44.87
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.38
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.64
28.64
0.54
16.78
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Atai Life Sciences Nv
Atai Life Sciences Nv
Buy
$410.0M
-88.17%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.0B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$100.2B
140.93%
26.28
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$565.1B
394.48%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.8B
117.3%
28.64
36.68%

Institutional Holdings

  • Morgan Stanley - Brokerage Accounts

    1.90%
  • BlackRock Inc

    0.82%
  • Marshall Wace Asset Management Ltd

    0.47%
  • Millennium Management LLC

    0.46%
  • Brown University

    0.43%
  • Mirae Asset Global Investments (Korea) Co Ltd

    0.38%

Corporate Announcements

  • Atai Life Sciences Nv Earnings

    Atai Life Sciences Nv’s price-to-earnings ratio stands at None

    Read More

Company Information

who we are: atai is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. our mission: we are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. our approach: by pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.

Organization
Atai Life Sciences Nv
Employees
133
CEO
Mr. Christian Angermayer
Industry
Commercial Services

FAQs